Cargando…
Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice
Recent work has suggested that fibroblast growth factor-21 (FGF-21) is a useful biomarker of mitochondrial disease (MD). We routinely measured FGF-21 levels on patients who were investigated at our centre for MD and evaluated its diagnostic performance based on detailed genetic and other laboratory...
Autores principales: | Morovat, Alireza, Weerasinghe, Gayani, Nesbitt, Victoria, Hofer, Monika, Agnew, Thomas, Quaghebeur, Geralrine, Sergeant, Kate, Fratter, Carl, Guha, Nishan, Mirzazadeh, Mehdi, Poulton, Joanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575582/ https://www.ncbi.nlm.nih.gov/pubmed/28825656 http://dx.doi.org/10.3390/jcm6080080 |
Ejemplares similares
-
Clinical features of the pathogenic m.5540G>A mitochondrial transfer RNA tryptophan gene mutation
por: Ng, Yi Shiau, et al.
Publicado: (2016) -
UK Reference Intervals for Parathyroid Hormone Using Abbott Methods
por: Mirzazadeh, Mehdi, et al.
Publicado: (2023) -
FGF19 subfamily members: FGF19 and FGF21
por: Dolegowska, Katarzyna, et al.
Publicado: (2019) -
De novo DNM1L mutation associated with mitochondrial epilepsy syndrome with fever sensitivity
por: Ladds, Emma, et al.
Publicado: (2018) -
A national perspective on prenatal testing for mitochondrial disease
por: Nesbitt, Victoria, et al.
Publicado: (2014)